Sitamaquine

DB04909InvestigationalSmall molecule

Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential treatment of visceral leishmaniasis.

Mechanism: The mechanism of plasmodicidal action of sitamaquine is not completely understood. Like other quinoline derivatives, it is thought to inhibit heme polymerase activity. This results in accumulation of free heme, which is toxic to the parasites.
Curator reviewed
Primary indication: Investigated for use/treatment in infectious and parasitic disease (unspecified).Curator reviewed
Formula / weight: C₂₁H₃₃N₃O · 343.5062 g/mol (avg)
Code names: DRG-0140 · WR 006026 · WR-6026

Resolves to

Compound

UNII5AIJ4TGC6BCAS57695-04-2ChEMBLCHEMBL57004PubChem42548

Clinical / RWD

PharmGKBPA166115581

Structure

InChIKeyRVAKDGYPIVSYEU-UHFFFAOYSA-NSMILESCCN(CC)CCCCCCNC1=CC(OC)=CC2=C(C)C=CN=C12

What you can answer from here — as of February 21, 2021

3Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which companies are running trials of Sitamaquine, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account